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The Ras inhibitor S-trans-trans farnesylthiosalicylic acid (FTS) inhibits active Ras, which controls cell proliferation,
differentiation, survival, and metabolism. FTS also inhibits HIF1a expression in cancer cells, leading to an energy crisis. The
synthetic glucose analog 2-deoxy-D-glucose (2-DG), which inhibits glycolysis, is selectively directed to tumor cells that exhibit
increased glucose consumption. The 2-DG enters tumor cells, where it competes with glucose for glycolytic enzymes. In cancer
models, as well as in human phase 1 trials, 2-DG inhibits tumor growth without toxicity. We postulated that under normoxic
conditions, tumor cells treated with FTS would be more sensitive than normal cells to 2-DG. We show here that combined
treatment with FTS and 2-DG inhibited cancer cell proliferation additively, yet induced apoptotic cell death synergistically both
in vitro and in vivo. The induced apoptosis was inferred from QVD-OPH inhibition, an increase in cleaved caspase 3, and loss of
survivin. FTS and 2-DG when combined, but not separately, also induced an increase in ﬁbrosis of the tumor tissue, chronic
inﬂammation, and tumor shrinkage. Overall, these results suggest a possible new treatment of pancreatic tumors by the
combined administration of FTS and 2-DG, which together induce pancreatic tumor cell death and tumor shrinkage under non-
toxic conditions.
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Ras proteins serve as key regulators of oncogenic processes
by governing cell proliferation, migration, and survival.
1–3
Inactive Ras proteins are attached to GDP and become
activated when receptors, in response to extracellular signals,
activate Ras guanine-nucleotide exchange factors to induce
exchangeofGDPforGTP.
4,5TheGTP-boundactiveRasmay
then target a multitude of downstream effectors, causing their
activation, which normally is transient owing to the hydrolysis
of GTP facilitated by Ras GTPase-activating proteins (Ras-
GAPs).
6–8 However, speciﬁc mutations at codons 12 and 13
render Ras insensitive to Ras-GAPs, and a mutation at codon
61 eliminates the intrinsic GTPase catalytic activity of the Ras
protein.
1 A large percentage of all cancer types either express
one of the mutationally activated Ras isoforms or harbor a
chronically activated Ras isoform owing to overexpression of
growth-factor receptors.
9,10 Therefore, Ras has long been
considered an appropriate potential target for directed
therapy, but attempts to target Ras with agents, such as
farnesyltransferase or methyltransferase inhibitors, have so
far been unsuccessful.
1
Over the last 15 years, we have elaborated a new concept
and developed a new class of Ras inhibitors that speciﬁcally
affect the active form of Ras. The concept is based on the
knowledge that the farnesyl moiety common to all Ras
proteins
11,12 not only serves as a lipophilic lipid anchor, but
also confers functional speciﬁcity on Ras.
1,11,12 Those
ﬁndings raised the possibility that the farnesyl group might
act as part of a recognition unit for speciﬁc anchorage lipids or
protein(s) that interact with Ras in the cell membrane. Such
Ras-binding partners were identiﬁed when it was shown that
galectin-1 and galectin-3,
13 respectively, act as speciﬁc
binding partners only of farnesylated active H-Ras and
K-Ras.
14–16 Hydrophobic binding pockets in these galectins
are the putative farnesyl-binding sites.
16,17 Galectin-1 drives
the formation and participates as an integral component of
H-Ras-GTP nanoclusters, the sites at which Raf is
activated.
18 Galectin-3 drives K-Ras-GTP nanoclustering,
leading to robust Ras signaling.
19 Interaction of nucleolin with
N-Ras and the epidermal growth factor receptor was recently
shown to synergistically support N-Ras transformation
in vitro.
20 Taken together, and assuming that compounds
that block farnesyl-binding sites would act as Ras inhibitors,
these ﬁndings point to the farnesyl-binding pockets as
excellent potential targets for Ras-directed therapy. The
original design of the speciﬁc synthetic Ras inhibitor,
S-trans-trans farnesylthiosalicylic acid (FTS; salirasib), was
indeed based on that assumption. FTS, which was designed
to mimic the farnesyl moiety in the carboxy terminal of Ras,
was found to induce accelerated dislodgement of Ras from
the cell membrane and its subsequent degradation.
21 FTS
also inhibits tumor growth, cell migration, and energy
metabolism in numerous cancer cell lines and many types of
cancer cells that exhibit high Ras GTP levels.
22–26 The most
recent clinical trials showed that oral salirasib treatment of
patients with pancreatic cancer increases survival rates
(http://www.concordiapharma.com).
Received 13.2.12; accepted 14.2.12; Edited by G Melino
1Department of Neurobiology, George S Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv, Israel
*Corresponding author: Y Kloog, Department of Neurobiology, George S Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv, Israel. Tel: þ972 3 496 6440;
Fax: þ972 3 640 7643; E-mail: kloog@post.tau.ac.il
Keywords: Ras; Ras-oncogenes; 2-DG; FTS; pancreatic cancer
Abbreviations: Ras-GAPs, Ras GTPase activating proteins; 2-DG, 2-deoxy glucose; FTS, salirasib, S-trans-trans farnesylthiosalicylic acid
Citation: Cell Death and Disease (2012) 3, e284; doi:10.1038/cddis.2012.24
& 2012 Macmillan Publishers Limited All rights reserved 2041-4889/12
www.nature.com/cddisBiochemical and gene-expression proﬁling experiments
strongly support the notion that the tumor growth inhibitory
effects of FTS result from inhibition of the active Ras and the
Ras-dependentsignalingthatparticipateintumorprogression
and maintenance.
22–26 An interesting additional outcome of
FTS treatment in tumor cells is energy crisis.
27 Malignant
cells, even under aerobic conditions, rely mostly on glycolysis
for their energy supply. In glioblastoma cells, for example, by
blocking the expression of HIF1a and hence the expression of
various enzymes of the glycolysis cycle, FTS causes a severe
energy deﬁcit, leading eventually to cell death.
27 This ﬁnding
provided the basis for a novel strategy in which FTS is
combined with compounds that block glycolysis by mechan-
isms other than blocking of HIF1a expression. The idea is to
use inhibitors of energy pathways that act independently of
the inhibitory activity of FTS, but inhibit enzymes that are
essential for tumor cell proliferation and survival.
The well-known metabolic inhibitor 2-deoxy-D-glucose (2-DG)
is a synthetic glucose analog that is selectively directed
to tumor cells, which, under hypoxic conditions, exhibit
increased glucose consumption facilitated by glucose trans-
porters.
28,29 Following its active transport into the tumor cells,
2-DG competes with glucose for key enzymes in glyco-
lysis.
28,29 The2-DG hasalso beenshowntoexhibitanti-tumor
activity in mouse and rat cancer models in vivo, including
models of sarcomas, adenocarcinomas, leukemias, melano-
mas, and bladder, colon, lung, and breast tumors.
30–32
Clinical trials aimed at evaluating the hormonal and metabolic
effects of glucose deprivation have shown that 2-DG,
although known to be toxic at high doses, does not cause
any serious adverse events at doses of up to 200mg/kg
(a single intravenous dose). In addition, when evaluated in
phase 1 clinical trials of patients suffering from recurrent solid
tumors, 2-DG was found to be safe and to exhibit some anti-
tumor effects (www.thresholdpharm.com).
We postulated that tumor cells treated with FTS would
be highly sensitive to metabolic inhibitors, probably signiﬁ-
cantly more sensitive than normal cells under normoxic
conditions. Here we demonstrate that the combination of
FTS and 2-DG synergistically attenuated pancreatic cancer
cell proliferation in vitro and caused signiﬁcant shrinkage of
pancreatic tumors in mice. Furthermore, this combined
treatment, both in vitro and in vivo, synergistically induced
apoptotic death of tumor cells, which was not induced by
FTS alone.
Results
Combined treatment with FTS and 2-DG synergistically
induces cell death of panc-1 pancreatic carcinoma
cells. FTS has been shown to inhibit the anchorage-
dependent and -independent proliferation of panc-1 and
MIA PaCa-2 pancreatic cell lines that harbor oncogenic
K-Ras, without inducing cell death.
24,26 The ﬁrst set of
experiments with 2-DG in the present study was aimed at
establishing a dosage at which the effect of 2-DG on cell
survival, when administered by itself, is minimal. Increasing
the ratio of 2-DG to glucose has been shown to result in
tumor cell death.
33 In this study, therefore, we employed a
non-toxic dose, 5mM 2-DG, combined with equimolar
glucose, which by itself is not toxic and has been shown,
for example, to enhance the cytotoxicity of topoisomerase
inhibitors.
34 The extent of death of 2-DG-treated panc-1 cells
in our experiments was small and was similar to that
observed in untreated controls (3% death), conﬁrming that
2-DG alone, at least at the dosage employed here, does not
affect panc-1 cell survival. We therefore used this non-toxic
dose of 2-DG for all subsequent experiments.
Next, we performed a four-armed experiment in which
panc-1 cells were treated with the vehicle (DMSO) only, 2-DG
alone, FTS alone, and FTS combined with 2-DG (FTSþ2-DG),
as described in Materials and Methods. Images from a
typical experiment performed with panc-1 cells are shown in
Figure 1a. Phase-contrast images show that treatment with
FTS alone (75mM) induced, as expected, a decrease in cell
number (by about 50%; Figures 1a and b). Treatment with
2-DG alone (5mM) also resulted in a decrease in cell number,
but the reduction was smaller (20–25%, Figure 1b). Hoechst
staining showed that neither of these single-drug treatments
caused a signiﬁcant increase in cell death, compared with the
control(Figures1aandc);thepercentagesofdeadcellsinthe
control (DMSO and 10mM glucose) and in cells treated with
2-DG (5mM 2-DGþ5mM glucose), or FTS (50mM
FTSþ10mM glucose or 75mM FTSþ10mM glucose) were
1.95±1.4, 2.5±4.5, 3.3±1.2, and 7.4±5.7, respectively
(Figure 1c). In contrast, combined treatment with FTSþ2-DG
causeda signiﬁcant increase in cell death; in cells treated with
FTS (50mM)þ2-DG, and with FTS (75mM)þ2-DG, the
percentages of dead cells were 11.5±5.8 and 30±9.3,
respectively (Figure 1c). Thus, under conditions in which
neither FTS nor 2-DG alone induced death of panc-1 cells,
signiﬁcant cell death was induced by their combination. This
result clearly points to a synergistic effect of the two drugs in
killing the panc-1 carcinoma cells.
Combined treatment with FTS and 2-DG induces cell
death in primary pancreatic carcinoma cell lines. We
then performed a similar set of experiments to determine
whether the effects of treatment with FTS and with 2-DG
observed in panc-1 cells could also be obtained in primary
pancreatic tumor cells, which better mimic the actual
disease. The cells used for this purpose were from the
recently characterized human primary pancreatic carcinoma
cell lines pp161, pp78, and pp109.
35 All three cell lines
possess an oncogenic K-Ras allele, and pp161 and pp78,
but not pp109, also bear a p53 loss-of-function mutation.
Hoechst staining showed that relative to the control, neither
of the single-drug treatments caused signiﬁcant cell death in
pp78 or pp161 cells (Figures 2a and c), but both induced
signiﬁcant death in pp109 cells (Figure 2b). However, the
combined treatment with 75mM FTSþ2-DG signiﬁcantly
increased cell death in all three cell lines, as in panc-1 cells.
The phase contrast images show that 75mM FTS alone
induced a decrease of about 50% in the total numbers of pp
109 (Figure 2e), pp161 (Figure 2f), and pp 78 cells
(Figure 2d). Treatment with 2-DG alone also resulted in a
decrease in cell number, but its effect was weaker than that
of FTS alone (Figures 2d–f). Interestingly, in pp78 and
pp161, both mutant p53 cell lines, the combined treatment
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line pp109, the effect was additive. The reason for this
phenomenon is not yet known. However, a beneﬁcial effect
of FTSþ2-DG on cell death was observed in all three
primary pancreatic carcinoma cells, as in panc-1 cells.
Combined treatment with FTS and 2-DG induces
caspase-dependent apoptosis in panc-1 cells.
Consistently with early reports, FTS (75mM) alone and
5mM 2-DG alone, both reduced the amount of Ras in the
cells, and a similar reduction was achieved with their
combined treatment (Figure 3a). To determine whether the
cell death induced by FTSþ2-DG in panc-1 cells was
apoptotic in nature, we used the pan-caspase inhibitor QVD-
OPH,
36 which inhibits the formation of cleaved (active)
caspase 3 (Figure 3a). We found that death induced by the
combination of FTS and 2-DG was signiﬁcantly inhibited by
QVD-OPH (Figure 3b), suggesting that the cell death
induced by FTSþ2-DG was, at least in part, apoptotic in
nature and dependent on caspase activation. This was
conﬁrmed by the observed increase in active (cleaved)
caspase 3 by FTS but not 2-DG, and by marked
enhancement of the cleaved caspase 3 by FTSþ2-DG,
apparently similar to that observed with staurosporine, a well-
known inducer of apoptosis (Figure 3a).
In previous studies, we found that FTS induces a marked
decrease in the apoptosis inhibitor survivin.
37 We therefore
examined the effect of FTSþ2-DG on survivin levels in
panc-1 cells. Although treatment with each drug on its own
decreased survivin levels to some extent, the combined
treatment completely eliminated the protein in a synergistic
manner (Figure 3a). This effect was even stronger than that
induced by staurosporine (Figure 3a). It is important to note
that treatment with FTSþ2-DG can block the main energy
source of cancer cells, both by reducing their expression of
HIF1a and by competing with glucose for glycolysis.
27 This
dual attack on energy metabolism, together with other anti-
cancer effects of FTS (such as attenuation of cell-cycle
progression
38), may lead to the catastrophic cellular stress
terminating in apoptotic cell death, as observed here.
Treatment with FTSþ2-DG synergistically induces
shrinkage of panc-1 tumors in nude mice. To examine
the effect of treatment with FTSþ2-DG in vivo, we implanted
Figure 1 Combinedtreatmentwith FTSand2-DGinducesdeathof panc-1cells.Thepanc-1cellswereseededat adensityof 10000cellsperwell in24-wellplates.After
24h,themediawerereplacedwithmediacontaining5%FCS,andthecellsweretreatedwith0.1%DMSO(control)orwithFTSattheindicatedconcentrations.After48h,the
media were again replaced with media containing 5% FCS, and the cells were treated with 10mM glucose or with 5mM glucose and 5mM 2-DG, and FTS was replenished.
After an additional 24h, the cells were stained with Hoechst and imaged using an Olympus ﬂuorescence microscope. Typical phase-contrast (upper panels) and Hoechst
ﬂuorescent images (lower panels) are shown in (a). The number of live cells, expressed as a percentage of the number of glucose-treated control cells (mean ±S.D.), is
presented in (b). Cell death (mean ±S.D.) was calculated as the number of Hoechst-positive cells counted in ﬂuorescence images expressed as a percentage of the total
number of cells counted in phase-contrast images (c). The experiments were performed in quadruplicate and repeated twice (n¼2)
FTS and 2-DG ameliorates pancreatic cancer
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of nude mice. Once palpable tumors were observed, oral
drug treatment was started (see Materials and Methods).
After 18 days, tumors were removed and weighed. As shown
in Figure 4, the average tumor weight in the group treated
with 2-DG (1000mg/kg) did not differ signiﬁcantly from that of
the vehicle-treated control group. Tumors treated with FTS
(60mg/kg), consistently with our previous ﬁndings, weighed
50% less, on average, than tumors excised from the vehicle-
treated controls.
24 Remarkably, however, treatment with
FTSþ2-DG resulted in tumors that weighed 90% less,
on average, than the controls, with no toxic side effects.
Some mice even exhibited tumor remission (data not
shown). These results clearly point to a synergistic effect
of FTSþ2-DG in inhibiting tumor growth, similar to the
synergism observed in vitro.
Typical H&E sections from tumors removed from the mice
for pathological analysis, as described in Materials and
Methods and shown in Figure 5, revealed the following
signiﬁcant changes in tumor morphology in the group treated
with FTSþ2-DG. First, in contrast to the similarity in
invasiveness between tumors from the control group and
from the groups treated by the single drugs, tumors treated
with FTSþ2-DG appeared much less invasive, and their
edges were not as irregular. Second, tumors treated with
either of the single drugs exhibited only slightly more ﬁbrosis
than the controls, especially at their edges, whereas tumors
treated with FTSþ2-DG exhibited marked ﬁbrosis around the
tumoredgesandattheleadingedges(Figure5,whitearrowin
hematoxylin and eosin (H&E)). Third, only the tumors treated
with FTSþ2-DG exhibited signiﬁcant chronic inﬂammation
(Figure 5, yellow arrow in H&E) and ﬁbrosis.
These changes in tumor morphology suggest that treat-
ment with FTSþ2-DG induced death of the tumor cells in the
tissue. To verify this notion, we stained tumor sections with
TUNEL to identify apoptotic cell death. As shown in Figure 5,
tumors treated with either of the single drugs showed some
TUNEL staining, which was altogether lacking in the control
Figure 2 Combined treatment with FTS and 2-DG induces cell death of primary pancreatic tumor cells. The three primary pancreatic tumor cell lines, pp78, pp109, and
pp161 were treated with FTS, 2-DG, or FTSþ2-DG as described in Figure 1 for panc-1 cells. Cell death, namely toxicity, (average ±S.D.), calculated as in Figure 1c as the
number of Hoechst-positive cells expressed as a percentage of the total number of cells, is presented in (a),( b), and (c) for pp78, pp109, and pp161, respectively.
The percentage of live cells (mean ±S.D.) relative to the untreated control is presented in (d), (e), and (f) for pp78, pp109, and pp161, respectively. The experiments were
performed in quadruplicate and repeated twice (n¼2)
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strong and signiﬁcant TUNEL staining, especially at the tumor
edges, indicating massive apoptotic cell death of the tumor
tissue (Figure 5). These ﬁndings conﬁrmed that treatment of
panc-1 tumors with FTSþ2-DG in mice signiﬁcantly inhibited
tumor growth by inducing apoptosis of the tumor cells.
Discussion
Activating mutations in Ras contribute to 30% of all human
tumors,
1 suggesting Ras as a prime target for cancer therapy.
The speciﬁc Ras inhibitor, FTS, successfully competes with
Ras chaperones for binding to active Ras, rendering it
inactive and thus causing inhibition of tumor cell proliferation
in vitro and in vivo.
14,15,20 In a recent study, it was shown,
moreover,that2-DGinducedHIF1a-independentapoptosisin
rhabdomyosarcoma cells.
39
In the present study, both FTS and 2-DG, when adminis-
tered assingle agents,were foundtoinhibit the proliferationof
panc-1 tumor cells, and when administered in combination,
their effect on such tumor growth was additive. In contrast,
whereas monotherapy with FTS or with a low (non-toxic) dose
of the glycolysis inhibitor 2-DG was incapable of causing
signiﬁcant death in this pancreatic tumor cell line, combined
administration of the two agents prompted their synergistic
effect resulting in signiﬁcant cell death, as demonstrated
in vitro by Hoechst labeling and in vivo byTUNEL. A beneﬁcial
effect of FTSþ2-DG on cell death was also obtained in three
human primary pancreatic carcinoma cell lines
35 (additively in
the pp109 cell line and synergistically in pp78 and pp161).
Proof that this cell death was apoptotic in nature camefrom its
observed inhibition by the apoptosis inhibitor QD-OPH
(Figure 3b), as well as from the increase in active (cleaved)
caspase 3 and decrease in pro-caspases 7 and 9 (not shown)
induced by FTSþ2-DG. Further evidence came from the fact
that the apoptosis inhibitor survivin, in which FTS by itself
induces a marked decrease,
37 was completely eliminated in
response to the combined treatment (Figure 3a).
It is important to point out that FTS itself is not cytotoxic
either in vitro or in vivo. Our in-vivo experiments in mice, in
which tumors induced by implantation of panc-1 cells were
treated with FTS combined with non-toxic dose of 2-DG,
resulted in shrinkage of pancreatic tumors and changes in
tumor morphology as described in detail in Results – is an
unexpected and novel ﬁnding.
Taken together, our results suggest a possible novel
treatment of pancreatic tumor by combining FTS and 2-DG
under non-toxic conditions. This can be expected to provide
synergistic tumor shrinkage, cell death, and possibly, also
remission.
Materials and Methods
Cell culture and immunoblotting. The human pancreatic cancer cell line
panc-1wasobtainedfromtheAmericanTissueCultureAssociation.Humanprimary
pancreatic cancer cells pp78, pp109, and pp161 were kindly donated by Andrea
Cavazzana (University of Pisa, Pisa). All cells were maintained in DMEM/10% fetal
Figure 3 Combined treatment with FTS and 2-DG induces caspase activation
inpanc-1cells.(a)Thepanc-1cellswereseededatadensityof10000cellsperwell
in six-well plates. After 24h, the media were replaced with media containing 5%
FCS, and the cells were treated with the vehicle (DMSO 0.1%; control) or with
staurosporine (STS, positive control), 5mM 2-DG, 75mM FTS, or FTSþ2-DG.
After 48h, the cells were lysed and the lysates were subjected to immunoblotting
with antibodies to cleaved caspase 3, survivin, pan-Ras, and b-tubulin (loading
control), as described earlier. The experiment was repeated twice (n¼2) with
similar results that show a marked increase in cleaved caspase 3 and decrease in
survivin in the combination of 2-DG and FTS treatment. (b) Induction of panc-1 cell
death by FTSþ2-DG is blocked by a caspase inhibitor. The panc-1 cells were
seeded at a density of 10000 cells per well in 24-well plates, as described for
Figure 3a. After 24h, the media were replaced with media containing 5% FCS, and
thecells were treatedwith DMSO (0.1%) or with FTS (75mM). After 48h, the media
were again replaced with media containing 5% FCS, 10mM glucose, or with 5mM
glucose and 5mM 2-DG, and FTS was replenished. The caspase inhibitor QVD-
OPh (20mM) was then added to the cells treated with FTSþ2-DG. After an
additional 48h, the cells were stained with Hoechst, imaged using an Olympus
ﬂuorescence microscope, and the percent cell death (toxicity) was calculated as
described in Figure 1b. Cell death (mean ±S.D.) was calculated as the number of
Hoechst-stained cells counted in ﬂuorescence images, expressed as a percentage
of the total number of cells counted in phase-contrast images (right panel). The
experiment was performed in quadruplicate and repeated (n¼2)
Figure 4 Combined treatment with FTSþ2-DG synergistically inhibits growth
of panc-1 tumors in nude mice. Nude CD1-Nu mice were xenografted with 7 10
6
panc-1 cells (subcutaneously above the right femoral joint). After 10 days, the mice
were separated into four groups: three experimental groups that received daily oral
doses of FTS (60mg/kg), 2-DG (1000mg/kg), FTSþ2-DG, or vehicle (0.5%
carboxymethylcellulose).Tumorswereextractedandweighedafter23days.Typical
results (mean ±S.D., n¼7; *Po0.05, Kruskal–Wallis test) obtained from one of
the two (n¼2) experiments performed are presented
FTS and 2-DG ameliorates pancreatic cancer
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95% air/5% CO2. Immunoblotting of Ras, cleaved caspase 3, survivin and beta-
tubulin were performed with speciﬁc Ab as previously described.
27 Materials used
for cell culture and determination of cell proliferation and death were all as
previously described.
27 FTS (batch number 012894-A-01-003) was provided by
Concordia Pharmaceuticals (Fort Lauderdale, FL, USA). 2-DG was purchased from
Sigma (St. Louis, MO, USA; cat number D3179).
Determination of cell proliferation and death. Cells (panc-1 or human
primary pancreatic tumor cells) were plated in 1ml of DMEM containing 5% FCS in
24-well plates at a density of 10000 per well and treated 24h later with FTS (50 or
75mM) or vehicle (0.1% DMSO). After an additional 48h, the media were replaced
by medium containing either 10mM glucose, or 5mM glucose and 5mM 2-DG.
FTS-treated cells were replenished with FTS or FTS plus 2-DG, or glucose with
0.1% DMSO (control). After incubation for 24 or 48h, as speciﬁed for each
experiment, theextent ofcelldeathwas determinedbystainingof thecellsfor5min
with Hoechst 33258 (1mg/ml). Stained nuclei (dead cells) were visualized under a
ﬂuorescence microscope. Phase-contrast images were also obtained. All
experiments were performed in quadruplicate and were repeated four times.
Datawerecollectedby imagingofeachwell.Thetotalnumberofcellswas obtained
by counting them in the phase-contrast images. The number of dead cells were
counted from the ﬂuorescence images and expressed as percentages (means
±S.D.) of the total number of cells.
Tumor implantation in mice. Nude CD1-Nu mice (8 weeks old) were
housed in barrier facilities on a 12-h light/dark cycle. Food and water were supplied
ad libitum. On day 0, 7 10
6 panc-1 cells in 0.1ml of phosphate-buffered saline
were xenografted subcutaneously just above the right femoral joint.
On day 10, tumors were measured and the mice were divided into four groups
for treatment with daily oral doses (300ml) of FTS (60mg/kg) and/or 2-DG
(1000mg/kg), or of 0.5% carboxymethylcellulose (control).
After 23 days of treatment, tumors were extracted and weighed. The experiment
was performed twice, and average tumor weights for each group were calculated
(means ±S.D., n¼7 per experiment). Statistical signiﬁcance of the results was
determined by non-parametric ANOVA (Kruskal–Wallis test).
Histology and TUNEL staining. Panc-1 tumors were extracted and
histological sections (5 and 10mm) were prepared. The 10-mm sections
were stained with H&E and were then imaged using an Olympus ﬂuorescence
microscope (Olympus Europa Holding GmbH, Hamburg, Germany) (original
magniﬁcation  200). H&E sections were also sent for thorough pathological
examination. The 5-mm sections were subjected to TUNEL according to
the manufacturer’s instructions (MBL International, Woburn, MA, USA) and were
then imaged using a Nikon ﬂuorescence microscope (Nikon lnstech, Tokyo, Japan)
(original magniﬁcation  200).
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